Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference

Rhea-AI Summary

Bellicum Pharmaceuticals (Nasdaq: BLCM) announced that Rick Fair, President and CEO, will present at the B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022, at 4 p.m. ET. A live webcast will be available on the company's website, with a replay accessible afterward. Bellicum specializes in controllable cellular immunotherapies for cancer, with innovative GoCAR-T® candidates like BPX-601 and BPX-603 that aim to enhance CAR-T cell therapy efficacy.

News Market Reaction – BLCM

+3.37%

+3.37% Session move

In the trading session that priced this news, BLCM gained 3.37%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the B. Riley Securities 2022 Virtual Oncology Conference. A corporate presentation is scheduled for Thursday, January 27, 2022 at 4 p.m. ET / 1 p.m. PT.

A live webcast of the presentation will be available from the Investor Relations section of the company website at Events & Presentations - Bellicum with a replay available shortly after the live event.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T^® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com or follow us on Twitter or LinkedIn.

Investors:
Robert H. Uhl
Managing Director
ICR Westwicke
858-356-5932
Robert.uhl@westwicke.com

 

FAQ

When is Bellicum Pharmaceuticals' presentation at the B. Riley Securities 2022 Virtual Oncology Conference?

The presentation is scheduled for January 27, 2022, at 4 p.m. ET.

How can I watch the Bellicum Pharmaceuticals presentation?

You can watch the live webcast on the Investor Relations section of Bellicum's website.

What are the main products being developed by Bellicum Pharmaceuticals?

Bellicum is developing controllable CAR-T cell therapies, specifically the GoCAR-T® product candidates BPX-601 and BPX-603.

What is the focus of Bellicum Pharmaceuticals?

Bellicum focuses on developing novel, controllable cellular immunotherapies for cancer.

Who will represent Bellicum Pharmaceuticals at the conference?

Rick Fair, President and CEO, will represent Bellicum at the conference.